Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

The efficacy and toxicity of combined paclitaxel and gemcitabine was evaluated in 54 chemotherapy-naive patients with metastatic non-small cell lung cancer (NSCLC). Gemcitabine i.v. 1000 mg/m(2)was administered on days 1 and 8 and paclitaxel 200 mg/m(2)as a continuous 3-hour infusion on day 1. Treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Douillard, J Y, Lerouge, D, Monnier, A, Bennouna, J, Haller, A M, Sun, X S, Assouline, D, Grau, B, Rivière, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363882/
https://www.ncbi.nlm.nih.gov/pubmed/11336467
http://dx.doi.org/10.1054/bjoc.2001.1784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363882/
https://www.ncbi.nlm.nih.gov/pubmed/11336467
http://dx.doi.org/10.1054/bjoc.2001.1784

Ejemplares similares